March 31, 2021 by admin 0 Comments

adsaf

March 30, 2021 by admin 0 Comments

Current and Future Trends in Organ Decellularization & Recellularization

The 8th Open Innovation
Current and Future Trends
in Organ Decellularization & Recellularization
Current and Future Trends in Organ Decellularization & Recellularization
- April. 02. 2021. FRI. 14:00 ~ 15:00 (GMT+8) -
OVERVIEW
The technique of whole-organ decellularization and recellularization.

ROKIT Healthcare offers a biotechnology platform that makes anti-aging
and organ regeneration come into a reality. ROKIT strives to extend the life of human kind
and improve the quality of life. In this webinar, we would like to discuss the present
and future of decellularized and recellularized organs the contents of existing research
methods for patient-specific organ transplantation and regeneration
using the ‘Organ regenerator’ with the subject of.Introducing a disruptive bio-automated device
that is equipped with the whole-organ decellularization and recellularization technique,
named Dr. INVIVO-CELL. It involves the removal of all the original cellular components
from an organ to produce scaffolds and bio-inks.
Also Dr. INVIVO-CELL recellularize a decellularized organ to produce transplantable organs.

For more details, please join the Open Innovation Seminar.
KEYNOTE SPEAKER

James Yoo, M.D. Ph.D.

  • Wake Forest Institute for Regenerative Medicine

Career Highlight

  • Harvard Medical School
  • Korea University Medical College

Jina Ryu, Ph.D.

  • Vice President of Kidney SBU, ROKIT HEALTHCARE, INC.

Career Highlight

  • Institute of Chemical Process, Seoul National University
  • Research Fellow in Boston Children’s Hospital / Harvard Medical School
INFORMATION
Subject
Current and Future Trends in Organ Decellularization & Recellularization
Date
April. 02. 2021, Friday (14:00 pm Korea Time)
Live Platform
Youtube Live
PROGRAM
ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare, INC.

March 12, 2021 by admin 0 Comments

제9기 정기주주총회 소집통지 (공고)

제9기 정기주주총회 소집통지 (공고)

 

주주님의 건승과 댁내의 평안을 기원합니다.
상법 제363조 및 당사 정관 23조에 의거하여 제9기 정기주주총회를
다음과 같이 소집하오니 참석하여 주시기 바랍니다.

 

– 다 음 –

1. 일 시: 2021년 3월 29일(월) 오전 9시
2. 장 소: ㈜로킷헬스케어 본사 (서울 금천구 디지털로10길 9, 12층) 대회의실
3. 회의 목적 사항:

가. 보고사항
제1호: 감사보고
제2호: 영업보고
제3호: 외부감사인 변경 보고
나. 결의사항
제1호: 재무제표 승인의 건
제2호: 사내이사 (유석환) 중임의 건
제3호: 감사 사임 및 선임의 건
제4호: 이사의 보수한도 승인의 건
제5호: 감사의 보수한도 승인의 건
제6호: 주식매수선택권 부여 승인의 건

4. 실질주주의 의결권 행사에 관한 사항

주주님께서는 금번 주주총회에 참석하여 의결권을 직접 행사하시거나,
서면에 의하여 의결권을 행사하시거나 또는 위임장에 의거 의결권을 간접 행사할 수 있습니다.

주주총회 관련 기타 주요 결의사항 및 참석 시 준비물에 대해서는
주주님께 우편으로 송부해 드린 소집통지서를 참고바랍니다.

​2021년 3월 12일

​(주)로킷헬스케어

​대표이사 유석환 [직인생략]

March 5, 2021 by admin 0 Comments

4D bioprinting developer, Rokit, preps for IPO

HONG KONG – Rokit Healthcare Inc. is working toward its goal of listing on the Korean stock exchange by July or August 2021. The Seoul, South Korea-based company will issue 12 million shares and targets setting the price range as early as July 2021. KB Securities Co. Ltd. and Mirae Asset will serve as organizers for the IPO.

February 8, 2021 by admin 0 Comments

Yanık tedavisinde dünyada bir ilk: Türkiye’de uygulanıyor

4D teknolojisi dünyada ilk kez yanık tedavisi için kullanılıyor. Ankara Şehir Hastanesinde kullanılan yöntemle hastaların kendi yağ dokusundan oluşan hücreler, 4 boyutlu yazıcı ile şekillendirilerek vücudun yanık olan bölgesine uygulanıyor.

4D (4 boyutlu) yazıcı teknolojisi dünyada ilk kez yanık tedavisi için kullanılmaya başlandı. Yaklaşık 3 ay önce Ankara Şehir Hastanesinde uygulanmaya başlayan yöntem ile vatandaşlar sağlığına kavuşuyor. Güney Koreli Rokit firmasının geliştirdiği Dr. Onvivo isimli 4 boyutlu yazıcı ile vücudunda yanıklar oluşan hastanın kendi yağ dokusu hücreleri alınarak tedavi ediliyor. Yanığın oluştuğu kısımların taranarak o bölgenin ölçüleri bilgisayara yükleniyor, daha sonra o bölgeyle birebir uyumlu kalıp oluşuyor ve hastadan alınan yağ hücreleri bir karışım ile birlikte belirli aşamalardan geçirilerek 4 boyutlu yazıcıya yerleştiriliyor. Yazıcı hazırlanan kalıba yanık olan yerle birebir aynı ölçülere sahip olan tedavi malzemesini boşaltıyor ve daha sonra hastaya uygulanıyor. Bu sayede daha önce yanık tedavilerinde kullanılan; hastanın vücudunun sağlam bir yerinden alınan deri ile yanık bölgenin tedavi edilmesi yöntemine gerek kalmıyor. Dünyanın çeşitli yerlerinde de kronik yaralar için uygulanmaya çalışılan, ama yeterli bilgi ve deneyim olmadığı için sonuca ulaşılamayan sistem; Ankara Şehir Hastanesi Yanık Tedavi Merkezi Sorumlu Hekimi Prof. Dr. Ahmet Çınar Yastı’nın koordinasyonu sayesinde 3 aydır başarıyla uygulanıyor.

“Bu dünyada ilk kez uygulanıyor, burada bizim ülkemizde ve bizim hastanemizde uygulanıyor”
Bu teknolojinin dünyada ilk kez Türkiye’de kendi yanık ünitelerinde kullanıldığına dikkat çeken Yanık Tedavi Merkezi Sorumlu Hekimi Prof. Dr. Ahmet Çınar Yastı, “Elimizdeki teknoloji ile biz fonksiyon kaybını ve bilhassa da kozmetik olarak renk farklılıklarını minimal seviyelere getirecek bir çalışma üzerinde devam etmekteyiz. Erken verilerden aldığımız sonuçlar bize bunun şuana kadar bildiğimiz ve kullandığımız tekniklere göre çok daha üstün ve çok daha iyi olduğunu göstermekte. Yine gurur verici olarak söylemek istiyorum; bu dünyada ilk kez uygulanıyor, burada bizim ülkemizde ve bizim hastanemizde uygulanıyor. Sonuçlarımız da yüz ağartıcı, biz de bunun gururunu paylaşıyoruz” şeklinde konuştu.

“Türk tıbbı bugün muasır medeniyetler seviyesini yakalamış hatta bazı konularda geçmiş durumda”
Türkiye’de tıbbın çok geliştiğini ve dünya çapında doktorlar yetiştiğini, vurgulayan Prof. Dr. Ahmet Çınar Yastı, “Daha önce, isim vermek istemiyorum ama 4-5 ülkede, hatta kuzey ülkelerinde denenip başarılı olamamış bazı vakalarda. Bizim burada başarılı sonuçlar aldığımızı gördük. Biz tabi işin mutfağında değil şuan klinik tarafındayız. Mutfak tarafı Kore’den geldi. Ama neyi, ne zaman ve nasıl kullanacağını bilmek, kullandığınız obje ne ise onun kadar kıymetli. Bu durumda zamanlama, yaranın hazırlığı, hastanın hazırlığı, takip etme süreciniz, yani pansuman sıklığına ve pansuman şekline kadar bunlar hep kıymetli parametreler. Doğru uygulamanın burada olduğunu onlardan öğrendik. Yani şunu demek istiyorum Türk hekimleri, Türk tıbbı bugün muasır medeniyetler seviyesini yakalamış hatta bazı konularda geçmiş durumda. Biz de bilim adamları olarak buna gereken desteği verelim ve halkımız da bunun refahını ve mutluluğunu yüreklerinde hissetsinler diye düşünüyorum” ifadelerini kullandı.

“Formula 1’de dünya şampiyonu olan arabanın pilotu, arabanın üretildiği ülkeden değil”
Önemli olan konunun teknolojinin nereden geldiği değil, nasıl kullanıldığı ve bu teknolojinin ülkemiz ve dünya insanlığına kazandırdıkları olduğunun altını çizen Prof. Dr. Yastı, “Kore’de çıkan bir teknolojiyle bugün eğer Türkiye’de ortak bir iş yapılıp uluslararası alanda iyi sonuçlar kazanan bir merkez oluyorsak; demek ki sadece Kore ile değil, dünyanın her yeri ile olan iletişimimizi ve birlikteliğimizi iyi kullanmak lazım. Bugün Formula 1 yarışlarına bakacak olursak, dünya şampiyonu olan arabanın pilotu, arabanın üretildiği ülkeden değil. Başka bir ülkenin pilotu arabayı sürüyor. Demek ki operasyon, koordinasyon daha iyiyi yakalamak için muhakkak ki gerekli. Bugün Türkiye için de biz öne vatandaşımızın daha sonra da bütün insanların iyiliğini düşünüyorsak tabi ki birlikte çalışmalar ve bilimin birlikte desteklenmesi çok önemli” diye konuştu.

“Hastanın herhangi bir vücut bölgesinde ekstra bir yara açılmadan, var olan yarasını iyileştirme sağlanmış oluyor”
Hastanın yağ dokularını toplayarak 4 boyutlu yazıcıya aktarılması işlemini gerçekleştiren, Ankara Şehir Hastanesi Yanık Tedavi Merkezi doktorlarından Genel Cerrahi Uzmanı Dr. Merve Akın, “Öncelikle uzun süreli kapanmayan yaraların kapanma yönteminde daha önce kullanılan, tarihsel olarak yıllardır kullanılan yöntemlere karşı avantajı; hastanın herhangi bir vücut bölgesinden ekstra bir yara açılmadan, var olan yarasını iyileştirme sağlanmış oluyor. Bildiğiniz gibi özellikle diyabetik hastalarda yara iyileşmesi çok zor olduğu için, hastanın yarasını bir başka yara açarak iyileştirmektense, herhangi bir yara açmadan alınan yağ hücresi, 4 boyutlu yazıcıda şekillendirilerek hastanın yarasına uygulanıyor. Böylece hastaların konforu daha fazla olmuş oluyor” açıklamasında bulundu.

Utku Şimşek – Erdinç Türkcan – Yunus Emre Kartal

January 26, 2021 by admin 0 Comments

Bioprinting Explained by ROKIT Healthcare CEO Seok-Hwan You

Bioprinting has the potential to revolutionize the healthcare industry by creating living human cells or tissues for use in regenerative medicine. Hundreds of thousands of people around the world are on transplant waiting lists. However, there aren’t nearly enough donor organs available to fill this demand. 

Imagine a technology that can create organs from scratch. That is the idea behind bioprinting. Bioprinting technology has not yet evolved to the point of printing organs. However, it has advanced enough to print simpler tissues such as skin, meniscus, cartilage, and even blood vessels. Yet bioprinting has massive potential to extend human life through the eventual printing and replacing of human organs. 

Seok-Hwan You is the founder and CEO of ROKIT Healthcare, one of the first biotech companies to 3D print PEEK, short for Polyether ether ketone, a bio-inert thermoplastic, and other high-performance materials. The company focuses on regenerative healthcare using bioprinting technology such as 3D biofabrication. As well as the development of patient-specific tissue and organ regeneration therapies. To gain a greater understanding of the bioprinting industry’s current state, we sat down with Seok-Hwan You. He gave his thoughts on the bioprinting sector and how ROKIT Healthcare will leverage bioprinting to improve the quality of life and health worldwide. 

What is Bioprinting? 

Bioprinting works very similarly to 3D printing. 3D printing uses a technique that deposits layers of material on top of each other. This creates a 3-dimensional object one layer at a time. While 3D printers use plastic or other materials, bioprinters use a printable material called “bio-ink.” A bio-ink is a mixture of living cells and other biomaterials. The key to creating a “bio-ink” is having access to a healthy supply from a living human (donor).

For optimal usage of bio-ink, raw materials should come from the patient. It is easier for the immune system to work with autologous tissues (meaning that the donor and recipient are the same people). The reason for this is because they are less likely to be rejected by the body. 

Bioprinters – How do they Work? 

Bioprinting offers a new opportunity for the development and preparation of personalized medicines. The advantages of bioprinters are that they minimize time and risk. As well as save costs for re-creating healthy tissue to implant into a patient. Seok Hwan, You believes that hospitals and clinics will soon need to have a bioprinter inside the operating theatre. This will be a new form of point-of-care personalized healthcare solution that maximizes the benefits of autologous regenerative technologies. 

ROKIT Healthcare’s signature 4D bioprinter is Dr. INVIVO, which ROKIT has already been supplying for material engineering and advanced prototyping in biomedical fields with materials like PEEK and ULTEM (polyetherimide). Now they are dedicated to providing bio-inks that are optimized for human tissue printing. Their ideal bio-ink formulations satisfy material and biological requirements that mimic cellular components found in tissue-specific microenvironments.

Seok-Hwan You -founder and CEO of ROKIT Healthcare

INVIVO Bio-inks

  • HumaTein – A bio-ink solution based on the cell-sheet technology that replicates the tunable stiffness of the tissue to be differentiated, ensuring optimal regenerative efficacy. 
  • INVIVO GEL – a gelatin-based bioink that is comprised of modified natural ECM components. The benefits of INVIVO GEL are that it has tailorable properties, good compatibility, and uniformity, which makes it easier to print while keeping structural stability.

Mr. You explains, “We envision integrating the 3D bioprinter and its applications into traditional healthcare services, realizing the idea of bioprinting as a medical service.” 

How Companies can benefit from Bioprinting

Many industries can benefit from bioprinting technology. The fields to which bioprinting applies range from tissue engineering and regenerative medicine to micro-tissue development for pharmaceutical testing as an alternative to animal experiments. Today, most new drugs have to go through an animal testing process. This ensures they are safe to use on humans. These animals are bred explicitly for testing and then euthanized once the testing process is finished. Bioprinting offers the potential to create functional, living, human tissue, or particular organs that are more accurate since they are based on human bio-inks. Therefore this process offers much more predictive results.

Some of the top clients of ROKIT Healthcare include: 

  • Research labs at Universities 
  • Government institutions 
  • Hospital Laboratories 
  • Pharmaceutical companies 

With 3D bioprinting-based therapy solutions such as skin and cartilage regeneration platforms, the applications of bioprinting can expand beyond life sciences research to use in medical practice. 

“Bioprinting must converge with other preventive medicine and diagnostic technologies, digitalization, and healthcare management strategies to be truly effective at the level of patient outcomes. ROKIT Healthcare seeks to address regenerative medicine and healthcare from a much wider vantage point, with bioprinting as an important – but not the only – area of our endeavors,” says ROKIT CEO You.

The Future of Bioprinting 

Seok-Hwan You says the next step in bioprinting is integrating 3D bioprinters and their applications into traditional healthcare services. This will play a significant role in making the idea of bioprinting as a medical device a reality. Hospitals worldwide are already adding dedicated facilities for bioprinting; however, the eventual goal is to have a bioprinter right next to every operating table. 

Besides this, there need to be more clinical trials on 3D bioprinted living tissues transplanted into patients. These are the first steps to advancing the technology to produce personalized organs to replace body parts as they wear out. ROKIT has already finished its clinical trials for bioprinting based skin regeneration for diabetic foot ulcer patients in India. Now the company has distribution deals with hospitals in several countries so they can offer skin generation bioprinting therapy to foot ulcer patients. 

Lastly, there are many kinds of bio-inks in the market today, such as synthetic and natural polymers. However, they are not all fit for use in the human body. Therefore, the future of bioprinting lies in bio-links based on the extracellular matrix (ECM) derived from the human body. The ECM is a kind of scaffold made up of proteins and other molecules. It gives cells the structural and biochemical support they need to live and multiply. In the future, it could eventually become the bio-ink used for the 3D printing of the first living, functioning human lung. 

“ROKIT Healthcare’s greatest focus lies not on synthetic plastics, but natural ingredients like human ECM, as supporting materials for 3D printed living cells,” said Mr. You.

Biggest Challenges

The biggest challenge that players in the 3D industry face is closing the gap between the available technology and clients’ actual needs in bioprinting research. Therefore, it is crucial to understand that bioprinting, is not only about manufacturing structures with structural stability. Rather it is about promoting cell growth and viability. Furthermore, ROKIT Healthcare is dedicated to building a base for developing next-generation bioprinting technologies and biomaterial applications. 

January 19, 2021 by admin 0 Comments

Treatments for Diabetic Foot Ulcers with Bioprinted Skin Patches

Diabetic Foot Ulcers

Before getting into the treatments for diabetic foot ulcers we first need to explain what they are. Diabetic foot ulcers are sores that occur on the soles of people with diabetes because of a breakdown in the skin tissue. The most common areas for these types of ulcers are on the underside of the toes or on the heels. Around 15 percent of diabetic people suffer from this problem. Once these ulcers occur, there is a high risk for amputation (14 to 24%). While the majority of them can heal (60 to 80%), it is very important to get treatment for diabetic foot ulcers right away.

Standard Treatments for Diabetic Foot Ulcers

In choosing the right treatment for a diabetic foot ulcer, it is important to first determine the cause. Is it related to nerve tissue? Is it related to blood vessels? Vascular ulcers are more serious. A specialist surgeon will need to do a full examination. They will ultimately decide whether the patient needs surgery and recommend the right treatment plan. Overall, it is important that the patient stays off their feet as much as possible. Being on your feet too often can make the ulcer become worse and grow in size. Below are some of the standard treatments for diabetic foot ulcers.

Types of treatments for diabetic foot ulcers:

  • Corrective footwear (diabetic shoes, casts, dressings, shoe inserts, or foot braces)
  • Removal of dead tissue (done by a doctor)
  • Skin grafting Antibiotics (a tissue sample of the ulcer will be sent to a lab to determine which antibiotic to prescribe)
  • Daily foot baths (the ulcer needs to be cleaned daily with antiseptic or a superoxide solution) with medical-grade honey in an ointment form

Bioprinted Skin Patches for Diabetic Foot Ulcers

After years of investigating ways to manage treatment for diabetic foot ulcers, Korean bioprinter manufacturer, ROKIT Healthcare has finally announced the success of a new treatment for diabetic foot ulcers through a customized tissue regeneration platform based on its 4D bioprinting technology. The treatment platform uses ROKIT’s 4D bioprinter Dr. INVIVO, which is the world’s first sterile, all-in-one 4D bioprinter/organ regenerator.

This new treatment has been globally commercialized after successfully testing on diabetic patients in India. Dr. INVIVO is already available in 48 countries. In addition to domestic patents, the company has obtained certifications from the European Medicines Agency (EMA) and is currently undergoing the required procedures from the Food and Drug Administration (FDA) that would allow commercialization in the United States. ROKIT’s autologous (meaning the recipient of the tissue is also the donor) skin regeneration procedure using Dr. INVIVO has already received regulatory approval for non-advanced therapy medicinal products (non-ATMP) by the EMA for the treatment of diabetic ulcers, pressure ulcers, scar revision, and burn wounds, meaning Dr. INVIVO can be used in the operating room.

ROKIT will continue its clinical trials in South Korea, North America, Europe, and East Asia. It is a fast, safe, and cost-effective regenerative therapy solution. It has been proven to result in a significant reduction in wound size after only a one-time treatment. In addition, it promotes skin regeneration.

Treatments for Diabetic Foot Ulcers – The Process of using Bioprinted Skin Patches

  • The process begins with fat tissue taken from the patient (for example through liposuction).
  • This fat tissue sample is then used to prepare an extracellular matrix (ECM) mixture to form a “bioink”. A “bioink” is a mixture of materials and cells.
  • The “bioink” is loaded into ROKIT’s Dr. INVIVO 4D bioprinter to produce a dermal patch.
  • Lastly, the damaged tissue is removed and replaced with the patch.

Most patients will show a complete closure of the wound in 2 to 5 weeks. Compare this to conventional treatments for diabetic foot ulcers, which can take months to heal and require multiple rounds of treatment or an extended period of observation. In addition, the treatment platform includes all of the procedures required to treat diabetic foot ulcers, including 3D scanning of the affected area, diagnosis, bioprinting with personalized “bioink”, and a procedure kit. However, the key to this new form of treatment was ROKIT’s Dr. INVIVO 4D bioprinter, which provides a fast regeneration solution for customized treatment of diabetic foot ulcers. Therefore, not only does it offer a precise and rapid process to print the patch, but Dr. INVIVO also creates a personalized therapy solution by building patient-specific designs.

Treating diabetic foot ulcers is only the beginning

ROKIT Healthcare’s unique treatment platform is already moving into cartilage regeneration for other forms of tissue damage and disease.

“Imagine a 3D bioprinting service in a hospital that can renew your damaged or worn-out body parts. The human body is composed of cells, proteins, and extracellular materials that we can also use as bioink to regenerate organs. Therefore we can regrow the injured body back to its original shape and function. 4D bioprinting technology is the best method to create human organs, such as skin, cartilage, and bone tissue. We are living in the era of the fourth industrial revolution that will ideally change human lifestyles, including our healthcare services. Now, ROKIT Healthcare is a pioneer in advanced cutting edge 4D bioprinting technology,” said Dr. Jeehee Kim, president of ROKIT Healthcare’s DFU and Skin Regeneration Strategy Business Unit. 

January 11, 2021 by admin 0 Comments

How Bioprinting can Benefit Industries in the Future

3D bioprinting has advanced significantly over the past decade. The sector has quickly become one of the leading segments in the 3D printing industry when it comes to innovation. Furthermore, the global bioprinting market is expected to reach over $4 billion by 2027

What is 3D Bioprinting?

Bioprinting utilizes proteins, living cells, and biomaterials to create biological materials. 3D printing in general distributes different materials left and right, up and down, and backward and forwards, to print an item layer by layer. 3D bioprinting uses living cells and biomaterials to print living structures layer by layer to create a natural living product. Therefore, 3DV bioprinters can build complex structures such as blood vessels and skin tissue. 

Previously, most bioprinting applications were used in the medical industry only. However, more and more industries are looking into 3D Bioprinting for innovative solutions. The reason for this is that 3D bioprinters have become a lot more sophisticated. They are able to deliver cells with high survivability and high precision. This is why many biotech companies, laboratories, hospitals, and universities around the world are exploring this field.

How Industries Can Benefit From 3D Bioprinting Technology

3D bioprinting has become a very hot trend for many industries. This is because it offers a precise and controlled layer-by-layer assembly of biomaterials in whatever 3D pattern desired. The capabilities of 3D bioprinting are vast so industries not just in medicine should be looking to incorporating this innovative technology.

1. 3D Bioprinting for the Medical Industry

3D bioprinting allows you to print biomedical parts that have the same properties as natural tissues. This is one of the reasons why 3D bioprinting is considered a crucial technology for the future of medicine. The ultimate goal is to eventually print a fully functional human organ. As the demand for organ transplants continues to grow every year, the solution that 3D bioprinting can bring becomes critical. Many researchers in the 3D bioprinting industry feel that within 20 years, transplant waiting lists will no longer exist. It is estimated that over 114,000 patients are waiting for an organ transplant in the United States. With 3D bioprinting technology, patients will have access to an organ that would be created from the very cells of their body. Therefore, there will be no risk of the organ being rejected by the body.

December 21, 2020 by admin 0 Comments

ROKIT America, developed NMN supplement product

NMN supplement is known to raise NAD+ levels and help improve ‘aging-related’ diseases (ie. cardiovascular, brain, diabetes, and immunity related diseases). ROKIT America’s NMN sales in Korea have increased by approximately 1,100% compared to that of April, 2020. It has now expanded its business to OEM sales for pharmaceutical companies in China, healthcare & pharmaceutical companies in UAE, and tertiary hospitals in Korea. NMN ingredients are currently pending approval as ‘Certified Functional Ingredients’ through the Korean FDA (MFDS)

December 21, 2020 by admin 0 Comments

ROKIT Healthcare’s wellness anti-aging center is to be opened in Hungary

Rokit has signed a term sheet with a Dubai based venture capital company to develop and operate a wellness center in Kőszeg, Hungary. The project aims to develop 3.3 hectare lot with ancient trees and a palace that will be renovated to a luxurious wellness anti-aging center for Rokit’s unique regenerative medicine technology and anti-aging products/services.As part of ROKIT’s IPO process in Korea, an Interim Audit was conducted by KPMG designated by The Financial Supervisory Service. Discussions on the Valuation and Liquidity Classification of Redeemable Convertible Preference Shares, and the Collectability of Account Receivables were done in ovember 2020. Rokit’s capital has increased $2.16 million (DRADS CAPITAL Inc.) plus $4.12 million (Vision Creator, a venture investor group focusing on high-tech, bio-healthcare industry in Korea and China).